Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations-Reference-Cited by-同舟云学术

Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations

Published:2024-07-02 Issue:8 Volume:14 Page:2285-2296
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Gooderham Melinda J.,de Bruin-Weller Marjolein,Weidinger Stephan,Cork Michael J.,Eichenfield Lawrence F.,Simpson Eric L.,Tsianakas Athanasios,Kerkmann Urs,Feeney Claire,Romero William

Funder

Pfizer Inc

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01200-5.pdf

Reference58 articles.

1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Prim. 2018;4(1):1. https://doi.org/10.1038/s41572-018-0001-z.

2. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–82. https://doi.org/10.1111/jdv.14891.

3. Nogueira M, Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept. 2021;11(4):e2021145. https://doi.org/10.5826/dpc.1104a145.

4. Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–72. https://doi.org/10.1016/j.jaci.2018.08.022.

5. Ariëns LFM, Bakker DS, van der Schaft J, Garritsen FM, Thijs JL, de Bruin-Weller MS. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159–70. https://doi.org/10.1177/2040622318773686.